The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MPN Workshop of the Carolinas 2024 | Survival outcomes of patients with MPN-AP/BP treated with current therapies
Anand Patel, MD, University of Chicago Medical Center, Chicago, IL, discusses the outcomes and conclusions from a multicenter analysis of patients diagnosed with myeloproliferative neoplasms (MPNs) in the accelerated or blast-phase (MPN-AP/BP). The study found a median overall survival (OS) of less than a year, with no significant difference among the three most common frontline treatment regimens. However, Dr Anand notes that OS was increased to 2.3 years after receiving an allogeneic hematopoietic stem cell transplant (alloSCT), suggesting that the goal for eligible patients with MPN-AP/BP is to control the disease prior to undergoing alloSCT to ensure durable survival. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria:BMS, AbbVie, Sobi; Research funding (institutional): Pfizer, Sumitomo, Kronos Bio.
